Back to results
US 5,843,924 AGranted
Intravenous alendronate formulations
AssigneeMerck & Co., Inc.
InventorsGerald S. Brenner, Musa M. Ghannam
Life of this patent
Estimating the term…
Abstract
Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
Claims7
A pharmaceutical composition comprising a pharmaceutically effective amount of alendronate, in a pharmaceutically acceptable aqueous carrier for intravenous application and a sufficient amount of a buffer to maintain the pH of the composition in the range of 4 to 8, said composition being isotonic with human blood.
Dependencies are inferred from the claim text.